Multimodal Approach in IBD Patients
NCT01705522 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 50
Last updated 2019-01-31
Summary
The investigators intend to assess the role of several biomarkers in the prediction of relapse in IBD. Clinical, laboratory and endoscopic data will be gathered and a predictive score will be derived in order to assess the relapse risk at 1 year.
Conditions
- Ulcerative Colitis
- Crohn's Disease
- Nonalcoholic Fatty Liver Disease (NAFLD)
- Vitamin D Deficiency
Sponsors & Collaborators
-
Clinical Hospital Colentina
lead OTHER
Principal Investigators
-
Theodor Voiosu, Md · Clinical Hospital Colentina
Eligibility
- Min Age
- 18 Years
- Max Age
- 85 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2012-10-31
- Primary Completion
- 2019-09-30
- Completion
- 2019-10-31
Countries
- Romania
Study Locations
More Related Trials
-
Fecal Biomarker Study for Patients With Ulcerative Colitis
NCT00780507 ·Status: COMPLETED
-
A Prospective Longitudinal Study of Fecal Microbiome and Calprotectin to Predict Relapse in Patients With IBD
NCT04079335 ·Status: UNKNOWN
-
Real Life Remote Monitoring of Mild, Moderate and Severe Infectious Complications in IBD by Patient Reported Assessment
NCT04151420 ·Status: COMPLETED
-
Biomarkers in Inflammatory Bowel Diseases
NCT02612103 ·Status: COMPLETED
-
Role of the Chemical Environment in the Pathogenesis of Inflammatory Bowel Disease
NCT03376230 ·Status: TERMINATED
-
Visceral Sensitivity in IBD (Irritable Bowel Disease) and IBS (Irritable Bowel Syndrome)
NCT02421705 ·Status: RECRUITING ·Phase: NA
-
Development of Novel Fecal Microbial Biomarkers for Inflammatory Bowel Disease
NCT05598489 ·Status: UNKNOWN
-
Characterization of Disease Related Changes in Inflammatory Bowel Disease Using Fecal Metabolite Profiling
NCT01666717 ·Status: COMPLETED
-
Is Relapse Rate Reduced by Home Monitoring of IBD Patients Tightly or on Demand by FC and Disease Activity?
NCT02492555 ·Status: UNKNOWN ·Phase: NA
-
Prediction of IBD Disease Activity in Individual Patients Based on PROMs and Clinical Data
NCT05578768 ·Status: UNKNOWN
-
A Study to Observe Vedolizumab and Anti-tumour Necrosis Factors (Anti-TNFs) Outcomes in Real-world Biologic Ulcerative Colitis (UC) and Crohn's Disease (CD) Participants
NCT03710486 ·Status: COMPLETED
-
Multi-omics to Predict Responses to Biologics in IBD
NCT05542459 ·Status: UNKNOWN
-
IBD Self-management Website and Home Faecal Calprotectin Monitoring
NCT03671980 ·Status: COMPLETED ·Phase: NA
-
Corporal Composition and Gut Microbiome Modification Through Exclusion Dietary Intervention in Crohn's Disease
NCT06933264 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
Study of Inflammatory Markers (VNN1) in Crohn Disease and Ulcerative Colitis.
NCT02304666 ·Status: UNKNOWN ·Phase: NA
-
Nutrition and Clinical Outcomes in IBD
NCT06550310 ·Status: RECRUITING
-
Prediction Model for Response to Biologics and Small Molecular Agent for UC
NCT05186623 ·Status: RECRUITING
-
Predictors of Non-response and Loss of Response in IBD Patients Treated With Anti-TNF
NCT01605188 ·Status: COMPLETED
-
Immunological Characteristics of Preclinical IBD
NCT05698745 ·Status: RECRUITING
-
Role of Altered Intestinal Permeability and Lipopolysaccharide in Thrombotic Risk and Vascular Injury in IBD Patients
NCT06772350 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
Setting up a Cohort of Patients With Inflammatory Bowel Disease and a Cohort of Patients Without Chronic Inflammatory Bowel Disease
NCT06502873 ·Status: RECRUITING ·Phase: NA
-
Study of Dietary Composition in Crohn's Disease
NCT04431700 ·Status: TERMINATED ·Phase: NA
-
Bologna IBD Markers
NCT02580864 ·Status: COMPLETED
-
Sub-optimal Response to Anti-Tumor Necrosis Factor's in Inflammatory Bowel Disease in Emerging Markets
NCT03090139 ·Status: COMPLETED
-
Eicosapentaenoic Free Fatty Acid and Fecal Calprotectin in Inflammatory Bowel Diseases
NCT02179372 ·Status: COMPLETED ·Phase: NA